LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Innocoll Holdings plc (“Innocoll” or the “Company”) (Nasdaq: INNL) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Innocoll shares and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
XARACOLL is Innocoll’s lead product candidate. Innocoll filed a New Drug Application (“NDA”) under the U.S. Food & Drug Administration (“FDA”) in October 2016.
On December 29, 2016, Innocoll revealed that it had received a Refusal to File letter from the FDA as to XARACOLL’s NDA. According to Innocoll, the FDA stated that XARACOLL should be considered a drug/device combination and asked Innocoll to submit further information.
When this information was released to the public, the value of Innocoll stock fell up to 66%, causing investors harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.